Consolidated Guidelines
Geneva, 2016
The End TB Strategy
2016 Update
Key population
Guidelines
Key Populations
UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Guidelines
June 2017
HIV strategic information for impact
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0